<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335362">
  <stage>Registered</stage>
  <submitdate>22/04/2010</submitdate>
  <approvaldate>28/04/2010</approvaldate>
  <actrnumber>ACTRN12610000334000</actrnumber>
  <trial_identification>
    <studytitle>Pharmacokinetics of NV06 in patients with advanced cancer</studytitle>
    <scientifictitle>Pharmacokinetics of  phenoxodiol, a novel isoflavone, following intravenous administration to  patients with advanced cancer</scientifictitle>
    <utrn>U1111-1114-6766</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pharmacokinetics of a novel isoflavone, phenoxodiol</healthcondition>
    <healthcondition>Pharmacokinetics of phenoxodiol after an intravenous bolus and after an intravenous infusion in patients with advanced cancer</healthcondition>
    <healthcondition>Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ntravenous phenoxodiol was given to cancer patients in two schedules: bolus (5mg/kg) and continuous infusion (2mg/kg/hr) up to 10 half-lives determined from the bolus infusion part of the study. The infusion was given 41-98 days after the bolus dose.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic behaviour of NV06 (phenoxodiol) as assessed by blood analysis</outcome>
      <timepoint>Variable timepoints were used in the assessment of phenoxodiol pharmacokinetics, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0 and 12.0 hours after infusion.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or females with metastatic disease from any solid tumour, age 18 to 70 years, normal haematological parameters and the provision of signed informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Leukemia or lymphoma, allergy to soy products, vegetarian diet or use of soy product more than three times a week, the use of sex steroids in the previous two months, antibiotic therapy within one month prior to the study period or at any time during the study, smoking of greater than 10 cigarettes/day, a prognosis of at least three months, and the known presence of central nervous system metastases,  active infection or other co-morbid disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patients with metastatic disease who had refused or failed at least one line of therapy were offered the opportunity to volunteer for this pharmacokinetic study. There was no randomisation.</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/05/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novogen Pty Ltd</primarysponsorname>
    <primarysponsoraddress>140 Wicks Road. NORTH RYDE NSW 2113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novogen Pty Ltd</fundingname>
      <fundingaddress>140 Wicks Road. NORTH RYDE NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study investigated the pharmacokinetics of phenoxodiol given as an intravenous bolus and a continuous intravenous infusion in a first-in-human study, to patients with advanced cancer.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress>Gray Street
Kogarah, NSW 2217</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Paul de Souza</name>
      <address>Cancer Care Centre
St George Hospital
Gray Street, Kogarah
NSW, 2217</address>
      <phone>+612-91133910</phone>
      <fax>+612-91133958</fax>
      <email>p.desouza@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Leanne West</name>
      <address>140 Wicks Road, Ryde, NSW, 2113</address>
      <phone>+612 9878 0088.</phone>
      <fax>+612 9878 0055</fax>
      <email>Leanne.West@novogen.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>